Présentation de l'entreprise
Genenta Science S.p.A. operates as a clinical-stage biotechnology entity focused on the development of hematopoietic stem cell gene therapies designed to treat solid tumors within the Italian market. The company's primary therapeutic focus is on glioblastoma, a type of brain tumor, utilizing its lead product candidate, Temferon, which is currently undergoing Phase 1/2a clinical trials. This organization functions within the broader healthcare sector, specifically the biotechnology industry, which is characterized by high capital expenditure requirements and a reliance on successful clinical trial outcomes to achieve commercialization. The company's market capitalization stands at $16.58M, while its annual revenue and total employee count are not disclosed in the available financial data. These valuation figures indicate that the firm is a micro-cap entity with a very small market presence, suggesting that its primary value proposition relies on the potential future success of its pipeline rather than current operational scale or profitability.
Santé financière
The company reports a net income of $-6,529,827 and an EBITDA of $-6,575,658 over the trailing twelve-month period, with revenue data unavailable for this reporting cycle. The substantial gap between the reported net income and EBITDA, while both are negative, reveals that the company's cost structure involves significant operating expenses that impact the bottom line, although without revenue data, the specific contribution of cost of goods sold versus operating expenses cannot be fully isolated. Free cash flow stands at $-3,095,756, indicating that the company is currently consuming cash reserves to fund its research and development activities rather than generating liquidity from operations. This negative cash flow position implies a limited degree of financial flexibility, necessitating the drawdown of existing cash reserves to sustain operations. All three reported margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is typical for pre-revenue or pre-commercialization biotechnology firms but confirms the absence of profitable sales activity to date. The company holds $28.15M in cash against $7.60M in debt, resulting in a debt-to-equity ratio of 34.81, which suggests a highly leveraged balance sheet relative to equity but manageable absolute debt levels given the cash on hand. The current ratio is exceptionally high at 14.15, indicating an abundance of liquid assets relative to current liabilities and a strong theoretical ability to meet short-term obligations if revenue were to commence. Return on equity is reported at -38.0% and return on assets at -17.7%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the context of traditional profitability measures, a status expected for entities in the clinical development stage.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not available due to the lack of net income, while the forward P/E ratio is listed at -1.09, a figure that typically arises in financial modeling when expected future earnings are negative or undefined. The disparity between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in continued losses or a lack of earnings consensus for the immediate future. The price-to-book ratio is 0.66, indicating that the company's market value trades at a discount to its book value, which can signal that the market assigns a lower value to the assets or that investors are skeptical about the asset base's ability to generate future returns. Alternative valuation metrics include a price-to-sales ratio that is unavailable and an EV/EBITDA of 0.59, suggesting a valuation that is technically low but misleading without the context of positive revenue or earnings. The stock has traded between a 52-week high of $10.00 and a 52-week low of $0.59, representing a range of over 16 times the low point. Without the specific current share price provided in the facts, the precise percentage distance from the high or low cannot be calculated, but the wide spread indicates high price volatility typical of small-cap biotechnology stocks. The beta value is 0.71, meaning the stock's price volatility is lower than the broader market, suggesting it is less sensitive to general market movements compared to large-cap equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as unavailable, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Consequently, it is impossible to determine the historical growth trajectory of the company's top line or profitability based on the provided data. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, reflecting a strategy of reinvesting all available resources and any potential future earnings back into research and development rather than distributing income to shareholders. Given the net income of $-6,529,827, the concept of a sustainable dividend payout is inapplicable as the company does not generate distributable earnings. The overall growth and income profile is characterized by a complete absence of current revenue growth or dividend income, with the entire financial narrative centered on the potential future conversion of clinical assets into commercial products.